COMMUNIQUÉS West-GlobeNewswire

Athenex to Present at the 2019 San Antonio Breast Cancer Symposium

23/09/2019 - 13:00

BUFFALO, N.Y., Sept. 23, 2019 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of [...]

Athenex to Highlight Oral Paclitaxel Clinical Programs Targeting Various Solid Tumors at the ESMO Congress 2019

23/09/2019 - 13:00

BUFFALO, N.Y., Sept. 23, 2019 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of [...]

Akcea Announces CEO Transition and Elects Two New Board Members

23/09/2019 - 13:00

Damien McDevitt, Ph.D. appointed interim CEO; Michael Yang and Joseph ‘Skip’ Klein join Board of Directors BOSTON, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate [...]

Amydis Awarded NIH Ph2A Grant for Cerebral Amyloid Angiopathy

23/09/2019 - 13:00

SAN DIEGO, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Amydis, Inc., a privately-held pharmaceutical company developing proprietary drugs to detect, monitor, and screen for amyloid-related diseases, announced today that they [...]

Scilex Holding Announces Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering

23/09/2019 - 13:00

SAN DIEGO, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Scilex Holding Company (Scilex), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE), announced that it has confidentially submitted a draft [...]

ReWalk Robotics to Present at the Sidoti & Company Conference on September 25th

23/09/2019 - 13:00

MARLBOROUGH, Mass. and YOKNEAM ILIT, Israel, Sept. 23, 2019 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (“ReWalk” or the “Company”) (Nasdaq: RWLK) today announced that Larry Jasinski, Chief Executive Officer, will present [...]

Cyclacel Pharmaceuticals to Present at the Ladenburg Thalmann 2019 Healthcare Conference

23/09/2019 - 13:00

BERKELEY HEIGHTS, N.J., Sept. 23, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on [...]

GW Pharmaceuticals receives European Commission approval for EPIDYOLEX® (cannabidiol) for the treatment of seizures in patients with two rare, severe forms of childhood-onset epilepsy

23/09/2019 - 13:00

Cannabidiol oral solution is the first plant-derived cannabis-based medicine to be approved by the European Medicines Agency (EMA) Cannabidiol oral solution contains highly purified, plant-derived cannabidiol (CBD), a [...]

Ovid Therapeutics Announces Positive Initial Data from Ongoing ENDYMION Open-Label Extension Trial of Soticlestat in People with Rare Epilepsies

23/09/2019 - 13:00

Sustained and Progressively-Improving Median Seizure Frequency Reduction Reaching 84-90% with Prolonged Treatment of Soticlestat in this Difficult-to-Treat Patient Population Soticlestat Continues to Advance in Rare [...]

GW Pharmaceuticals receives European Commission approval for EPIDYOLEX® (cannabidiol) for the treatment of seizures in patients with two rare, severe forms of childhood-onset epilepsy

23/09/2019 - 13:00

Cannabidiol oral solution is the first plant-derived cannabis-based medicine to be approved by the European Medicines Agency (EMA) Cannabidiol oral solution contains highly purified, plant-derived cannabidiol (CBD), a [...]

Cambrex Corporation Announces Expiration of “Go Shop” Period Under Merger Agreement

23/09/2019 - 12:40

EAST RUTHERFORD, N.J., Sept. 23, 2019 (GLOBE NEWSWIRE) -- Cambrex Corporation (NYSE: CBM) (the “Company” or “Cambrex”) today announced the expiration, as of 12:01 a.m., Eastern Time, on September 22, 2019, of the 45-day [...]

Precision BioSciences Appoints David Thomson, PhD, as Chief Operating Officer

23/09/2019 - 12:30

DURHAM, N.C., Sept. 23, 2019 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a genome editing company dedicated to improving life through the application of its pioneering, proprietary ARCUS ® platform, [...]

Plus Therapeutics to Receive $4.6MM Reimbursement Payment

23/09/2019 - 12:10

AUSTIN, Texas, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”) today announced that it received notice from the U.S. Department of Health and Human Services / Office of the [...]

Philips underlines commitment to Universal Health Coverage at UNGA 74

23/09/2019 - 11:00

September 23, 2019 New report shows how to address the challenges of implementing digital health technology – a catalyst for achieving Universal Health Coverage (UHC) Philips Chief Medical Officer Jan Kimpen discusses [...]

TLC to Present Preclinical Data on TLC178 at ESMO 2019

23/09/2019 - 11:00

TLC178 shows potential as a treatment for sarcomas, with enhanced efficacy, reduced toxicity and decreased dosing frequency SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Sept. 23, 2019 (GLOBE NEWSWIRE) -- TLC (Nasdaq [...]

Active Biotech: New data on laquinimod from the Phase 2 LEGATO-HD study in Huntington’s disease will be presented at the International congress of Parkinson’s disease and movement disorders

23/09/2019 - 08:30

Lund Sweden, September 23, 2019 - Active Biotech (NASDAQ STOCKHOLM: ACTI) announces that new data from exploratory analysis of the Phase 2 LEGATO-HD study of laquinimod in Huntington’s disease will be presented at the [...]

Innate Pharma announces clinical data presentations on IPH5401 and monalizumab at ESMO 2019

23/09/2019 - 07:00

INNATE PHARMA ANNOUNCES CLINICAL DATA PRESENTATIONS ON IPH5401 AND MONALIZUMAB AT ESMO 2019 Preliminary results of IPH5401 STELLAR-001, a dose escalation Phase I study in patients with advanced solid tumors 1-year [...]

Innate Pharma annonce la présentation de données cliniques sur IPH5401 et monalizumab au congrès de l’ESMO 2019

23/09/2019 - 07:00

INNATE PHARMA ANNONCE LA PRÉSENTATION DE DONNÉES CLINIQUES SUR IPH5401 ET MONALIZUMAB AU CONGRÈS DE L’ESMO 2019 Données préliminaires issues de STELLAR-001, l’étude de Phase I en escalade de dose évaluant IPH5401 chez [...]

Press Release Biocartis NV: Five Idylla™ Performance Studies to be Presented at ‘European Society for Medical Oncology’ congress

23/09/2019 - 07:00

PRESS RELEASE 23 September 2019, 07:00 CEST Mechelen, Belgium, 23 September 2019 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), today [...]